Axcellant have a rich history of supporting the development of many agents that are currently being used in routine clinical practice to extend the life or cure patients with a range of solid tumours and haematological malignancies.

Whether it is the various generations of monoclonal antibody epidermal growth factor receptor (EGFR) inhibitors; small molecule tyrosine kinase inhibitors; poly ADP ribose polymerase (PARP) inhibitors; antiandrogens and the various immunotherapies we have been very much at the heart of their development and continue to be involved in the subsequent generations of these important products.

The highly specialised skills of our regulatory and clinical operations team have also given us the opportunity to be involved with advanced therapies such as chimeric antigen receptor T-cell (CAR-T) therapies and gene transfer.

We have successfully executed many programmes targeting niche cohorts and involving broad multidisciplinary teams at hospitals (e.g.: radioembolisation, contrast for cardiological imaging).

Axcellant medical device division is rapidly building a strong reputation in the area of wound healing.

We have supported numerous medical devices/technology companies in providing integrated end-to-end solutions from generating a target product profile to marketing applications.

Our team have led the development of products in various disorders of the central nervous system.

From novel pharmaceuticals in Multiple Sclerosis to medical devices in Alzheimer’s disease and advanced therapeutics in Parkinson’s disease, our team have built a strong network with neurologists, neuroradiologists and their teams globally.

We can deliver studies for disorders of the central nervous system faster and to a higher standard.

Our broad diversity within our professional network gives us a pole position in supporting you with your research question(s).

Our team have supported the development of pharmaceuticals and medical devices that are helping millions of patients globally with contraception, gynaecological therapy and testosterone deficiency.

During the early stages of development, our organisation was fortunate to be deeply involved with immunotherapies (monoclonal antibodies) for haematological cancers and for the treatment of multiple sclerosis.

Through these early experiences, we have gained valuable insights into the development and operations of studies involving monoclonal antibodies and have successfully leveraged these insights in operationalising studies with immuno-oncology agents.

Our scientific advisory team comprise experts in the highly specialised niche of immunology and immuno-oncology.

They add significant value in defining target populations of patients across tumour types and disease areas.

We have joined organisations on courageous journeys to address bold research questions.

Through this, we have developed a wealth of expertise within therapeutic areas.

Pulmonary arterial hypertension, chronic obstructive disease and respiratory syncytial virus in the paediatric population are areas our team understands very well.

From factor Xa inhibitors for anticoagulation to statins for reducing low-density lipoprotein, we are proud to have helped in the generation of clinical evidence that has led to the benefit of many patients globally.

Our team is well acquainted with working with organisations of all sizes to operationalise studies in the cardiovascular disease area.

We are supporting research internationally in various stages of cardiovascular disease, from diagnostic imaging through to medical treatment and revascularisation surgery.

We feel privileged to have supported organisations developing therapies for the treatment of severe psoriasis and acne.

It is reassuring to see the impact these products have made on the well-being of patients globally.

We are the ideal size to form meaningful partnerships and deliver a personalised service to our customers.

The treatments for diabetes and thyroid disorders are constantly improving, whether it is through new formulations or a completely new product.

Working in partnership with endocrinologists, we have supported the clinical development of products that have been successfully marketed, thereby improving the quality of life for patients and providing value to healthcare payers.

Our team have the knowledge to successfully research generics and biosimilars.

We have empathy with health care systems and patients globally and understand the need to explore practices enabling affordable treatments for terminal or life-threatening illnesses.

We have the know-how to drive efficiency in the clinical development of biosimilars.

Our processes, systems and training methodology are quality by design.

Approximately 400 million people worldwide suffer from an orphan disease. With 8000 known rare diseases, it is an area of high unmet need from diagnosis to treatment.

In our capacity as a purpose-driven organisation, we have been very keen to support organisations in acquiring the orphan designation in Europe and the US.

Our epidemiologists work very closely with our regulatory team to review all available data and complete the regulatory application for designation.

With the market exclusivity associated with orphan indications, we have inclusive integrated solutions to optimise the success of projects in adult and paediatric populations.

We have collaborated successfully with gastroenterologists/hepatologists to address some very compelling research questions in patients with Child-Pugh B&C cirrhosis, non-alcoholic steatohepatitis and also ulcerative colitis.

Our team does not give up in the face of adversity.

In niche cohorts where patient recruitment is likely to be a challenge, we identify this early during our planning and provide integrated patient recruitment solutions that have been tried and tested.

At Axcellant, we consider ourselves a community of medical professionals, pharmacists, and scientists.

We feel excited about the site-saving research that is being performed in academia and industry in the areas of macular and retinal degenerations.

We consider ourselves fortunate to have a team that has made contributions to the generation of clinical evidence in diabetic retinopathy, uveitis and glaucoma.

Resistance to the current generation of antibiotics is becoming an increasingly significant global health concern.

We are collaborating with academia and biotechnology organisations to support the pursuit of researching a new generation of antibiotics so that what is routine now can continue to be routine in 15 years.

We have a team of indefatigable clinical research scientists who will approach your project with passion, energy, and curiosity that is very difficult to match.

From our CTAs to the CEO, we are intrigued by the science and feel the responsibility to translate this on behalf of the sponsors.